Psychedelic Nasal Spray for Depression: What the Research Shows

What BPL-003 Actually Is

Most conversations about psychedelic medicine center on psilocybin or ketamine. A newer compound is now drawing serious scientific attention: BPL-003, an intranasal formulation of mebufotenin benzoate, which is a stabilized salt form of 5-MeO-DMT. Developed by Beckley Psytech and atai Life Sciences (now merged as AtaiBeckley), BPL-003 is designed to be administered as a psychedelic nasal spray for depression in a supervised clinical or outpatient setting.

The compound delivers 5-MeO-DMT directly through the nasal passage, producing rapid absorption and a short but intense psychedelic experience. Unlike psilocybin sessions that typically run four to six hours, BPL-003 produces its primary effects in a much shorter window. That difference is clinically significant, because it changes how this treatment fits into real-world healthcare settings and lowers the logistical barrier for providers and patients alike.

What the Clinical Evidence Actually Shows

The research behind this psychedelic nasal spray for depression is at an early but compelling stage. Here is what we know so far.

A Phase 2b randomized trial involving 193 participants with treatment-resistant depression found that both the 8 mg and 12 mg doses produced statistically significant reductions in depression scores, measured using the Montgomery-Asberg Depression Rating Scale (MADRS), as early as day two after a single administration. The 8 mg dose showed a mean 12.1-point reduction from baseline at day 29, compared to a 5.8-point reduction in the active control group. Effects were sustained over at least eight weeks in many participants.

A separate open-label Phase 2a study published in the Journal of Psychopharmacology in February 2026 followed 12 patients with moderate-to-severe treatment-resistant depression who received a single 10 mg dose. Mean MADRS scores dropped by 12.6 points by day two and remained reduced across a 12-week observation period. Ten of the twelve participants met discharge readiness criteria within 90 minutes of dosing, and the majority were considered clinical responders at one or more follow-up points.

In October 2025, the FDA granted BPL-003 Breakthrough Therapy designation, a status reserved for drugs that show meaningful improvement over existing therapies for serious conditions. Phase 3 trials are expected to begin in the second quarter of 2026.

This is where things get more nuanced. These are still early-stage results, and most participants in these trials received psychological support alongside the dosing session. The data is promising, but it is not a finished story, and the researchers themselves are measured in how they describe what remains unknown.

How BPL-003 Differs from Existing Options

The closest approved comparison is esketamine (Spravato), the FDA-approved nasal spray for treatment-resistant depression derived from ketamine. BPL-003 belongs to a different pharmacological class entirely. Where esketamine primarily blocks NMDA receptors, 5-MeO-DMT acts on serotonin receptors and produces a qualitatively different type of experience, including what many researchers and participants describe as a complete mystical experience, as measured by the Mystical Experience Questionnaire.

In practice, BPL-003 sits closer to classical psychedelic-assisted therapy in character, even though its duration is far shorter. That brevity is one of its clinical advantages: participants in the Phase 2b trial were generally ready for discharge within two hours, which aligns with outpatient workflows. But a two-hour window can still produce a significant perceptual and emotional shift, which means the preparation and integration question becomes more acute, not less.

Why Integration Is Not a Secondary Concern

Clinical trials are designed to measure symptom reduction at defined intervals. They are not designed to answer the harder question of what makes those reductions last, and the gap between a statistically significant MADRS score reduction and a person actually living better six months later is wide enough to matter.

People who experience rapid symptom relief from a psychedelic intervention often describe it as a window opening, a brief period of reduced psychological rigidity in which new perspectives feel more accessible and ingrained patterns feel less fixed. What happens in that window has real consequences. Without structure to support it, old stress responses and unresolved emotional material tend to reassert themselves.

At JourneyŌM, integration is not supplementary care. It is where the actual work happens. Our guides work with seekers before an experience to establish intention and context, and afterward to help process what emerged and translate insights into sustainable change. This looks different for each person. For some it means structured check-ins over several weeks. For others it involves practices like reflective journaling, breathwork, or somatic work to help the nervous system settle into new patterns. The goal is not to relive the experience but to carry what was genuinely useful forward into daily life.

What This Means for Seekers Right Now

BPL-003 is not available outside of clinical trials as of early 2026, and the Phase 3 program is still in preparation. If you are living with treatment-resistant depression and are curious about this class of treatment, a few things are worth understanding now.

First, the landscape of legally accessible psychedelic-assisted options is broader than most people realize. Ketamine therapy is available through licensed providers in most US states. Psilocybin services are legal in Oregon and Colorado. These are not identical to BPL-003, but they involve similar principles around preparation, set and setting, and integration support, and they are available today.

Second, the preparation you do before any psychedelic experience and the integration work that follows are not add-ons. The clinical literature across multiple substances and study designs consistently identifies psychological support as a key variable in outcomes. Engaging with this process thoughtfully, with a vetted guide, is one of the most meaningful decisions a seeker can make.

Third, anyone considering a psychedelic experience for depression should be working with a qualified healthcare provider to assess appropriateness, identify contraindications, and coordinate with any existing treatment. This is not a self-directed process, and safety depends on that coordination being in place from the start.

Where the Research Is Heading

AtaiBeckley is advancing BPL-003 into a pivotal Phase 3 program, with initiation expected in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA. A separate Phase 2a cohort is evaluating a two-dose induction regimen of 8 mg followed by 8 mg, with initial data expected in late 2026. Researchers are also investigating BPL-003 for alcohol use disorder, which would expand its potential therapeutic scope considerably.

The trajectory is meaningful. Breakthrough Therapy designation, peer-reviewed publication in the Journal of Psychopharmacology, and sustained MADRS score reductions across multiple study designs all point to a compound worth watching closely. Dosing optimization, long-term safety data, and the precise role of psychological support remain open questions, and the people most likely to benefit from this research are those who engage with it with that understanding in place.

If you are curious about psychedelic-assisted approaches to depression and want to understand your options carefully and safely, JourneyŌM is here to help.